AMA, reality is, XKEM is a biotech in its infancy. They will not have any cash to put into a buy-back any time in the next 10 years. They will put all the cash genertated into new drugs and R&D, and FDA apps and growing the business. The truth is, an RS would be required to clean up the share structure, and move us to a higehr exchange. This would be good for us in the long run, but will be very hard in the short term. The timing of an RS is very importnat here. An RS, when there exists a proven history of revenue and earnings growth, will be accepted by the market. An RS before then, will be viewed as a wind up for another round of dilution. I can assure you that I have had this discussion with the compoany several times. They are well aware of the issues surrounding an RS, and will not even entertain the idea of an RS until reveneue and profit growth history is established. For now, we must live with a large O/S. I think we will do just fine as is.